Soligenix, Inc. (SNGX) Monday said it received orphan drug designation for MarVax, proposed for the prevention and post-exposure prophylaxis against Marburg marburgvirus (MARV) infection.
Marburg marburgvirus causes Marburg Virus Disease, a highly related disease to the more commonly known Ebola Virus Disease.
Along with seven-year market exclusivity for the drug on approval, orphan drug designation provides with certain financial and regulatory benefits including government grants for conducting clinical trials, waiver of FDA user fees for the potential submission of a Biologics License Application (BLA), and some tax credits.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.